Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is likely supported by a differentiated binding profile, the analyst tells investors in a research note. The firm says the data support further development in placebo-controlled study for additional validation in AD and beyond. If successful, BSI-045B could be the first anti-TSLP in the crowded AD space, providing a differentiated mechanism of actin improved efficacy and safety, contends Jefferies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
- Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler
- Aclaris Therapeutics Expands Pipeline and Strengthens Leadership
- Aclaris Therapeutics enters global license agreement with Biosion
- Aclaris Therapeutics to sell 35.5M shares at $2.25 in private placement
Questions or Comments about the article? Write to editor@tipranks.com